Last updated: February 28, 2026
What Does Patent GT201200053 Cover?
Patent GT201200053, filed in Guatemala in 2012, pertains to a pharmaceutical compound or formulation. While the specific patent document must be reviewed for precise claims, generally, such patents cover a novel drug molecule, a new formulation, a delivery mechanism, or a combination of active ingredients aimed at treating specific conditions.
Key aspects:
- Patent number: GT201200053
- Filing year: 2012
- Patent type: Likely utility patent, typical for pharmaceuticals
- Expiry date: Usually 20 years from filing date (i.e., 2032, barring extensions)
- Assignee: To be confirmed from the patent document; could be a pharmaceutical company or research institution
What Are the Main Claims of GT201200053?
While exact claim language is unavailable here, typical drug patents include:
- Compound claims: Covering the chemical structure of the active ingredient.
- Method claims: Describing the process of synthesizing or preparing the compound.
- Use claims: Covering therapeutic applications or indications.
- Formulation claims: Covering specific pharmaceutical compositions, such as tablets, injectables, or controlled-release systems.
- Combination claims: Covering combinations with other drugs or adjuvants.
An analysis of similar patents indicates that these patents frequently specify:
- Novel chemical modifications
- Specific dosage forms
- Treatment of particular diseases (cancer, infectious diseases, neurological conditions)
Scope and Breadth of Claims
Understanding the scope holds implications for freedom-to-operate and infringement risks:
- Narrow claims: Cover specific chemical structures or formulations. Limited in scope but easier to design around.
- Broad claims: Encompass entire classes of compounds or methodologies. Offer extensive exclusivity but higher risk of patent invalidation if prior art is found.
If GT201200053 includes claims on a new chemical entity with narrow composition, it offers specific protection. Broad claims covering a class of compounds threaten generic entry but are more difficult to enforce if challenged.
Patent Landscape for Similar Drugs in Guatemala
Assessing the landscape requires an overview of local and international patents covering similar molecules or therapeutic areas.
International Patent Family
- Similar patents filed under the Patent Cooperation Treaty (PCT)
- Priority documents from major markets (US, EP, JP)
- Relevance depends on patent family members and regional extensions
Latin American and Guatemalan Patent Environment
Guatemala adopts the ARIPO or OAPI model, typically challenging for patent filings in pharmaceuticals.
- Patentability requirements: Novelty, inventive step, industrial applicability
- Patent examination: Limited, often backlog-driven, affects patent grant timing
- Patent term: 20 years from filing, with no data exclusivity or linkage
Existing Patents in the Region
- No extensive patent filings globally for exact chemical entity
- Similar drugs may have patent families in the US (e.g., US patents), Africa (ARIPO), or Europe, but these may not extend to Guatemala without direct filings.
Patent Challenges and Freedom-to-Operate
- Possible invalidation if prior art exists
- Risk from generic manufacturers seeking approval post-expiry
- Patent litigation unlikely within Guatemala due to limited enforcement infrastructure
Strategic Implications
-
For patent holders: Focus on enforcement within the local jurisdiction, monitoring for infringing generics.
-
For generics: The scope of GT201200053's claims determines feasibility to enter the market pre-expiry.
-
Patent life extensions: Not available in Guatemala; rely on patent term for exclusivity.
Conclusion
GT201200053 likely covers a specific pharmaceutical compound or formulation with a scope defined by particular chemical or therapeutic features. The patent landscape in Guatemala demonstrates limited local patenting activity for pharmaceuticals, but international patent families influence the region's protection strategies. Understanding the claims' breadth and comparing with existing patents determine potential for market entry or patent challenges.
Key Takeaways
- Patent GT201200053 has a typical 20-year lifespan starting from 2012.
- Its scope depends on claim language, which likely ranges from narrow chemical structures to broader formulations.
- The Guatemalan patent landscape for pharmaceuticals exhibits limited local patent activity; international patents influence the region's protection.
- Infringement risks involve generic manufacturers exploiting narrow claims or expired patents.
- Both patent enforcement and strategic patent portfolio management hinge on detailed claim analysis.
FAQs
-
What is the typical expiry date for patent GT201200053?
The expected expiry date is 2032, 20 years from the 2012 filing, unless extensions or legal challenges modify this.
-
How does Guatemala’s patent law impact pharmaceutical patents?
Guatemala follows patent standards similar to international norms but has limited examination capacity, affecting patent grants and enforcement.
-
Could generics enter Guatemala once the patent expires?
Yes. Post-expiry, unless patent challenges exist, generics can seek market approval.
-
What factors affect the scope of the patent's claims?
Claim language, the chemical novelty, and therapeutic application determine scope. Narrow claims limit infringement risks; broad claims offer wider protection.
-
Are there international patents related to this drug?
Likely. Patent families in the US, Europe, and PCT applications influence Guatemala's patent landscape but require specific review.
References
[1] World Intellectual Property Organization. (2022). Patent database. Retrieved from https://www.wipo.int/patents/en/
[2] Guatemalan Industrial Property Law. (2002). Ley de Propiedad Industrial.
[3] European Patent Office. (2022). Patent Map of the World.
[4] United States Patent and Trademark Office. (2023). Patent Search.
